<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04547998</url>
  </required_header>
  <id_info>
    <org_study_id>CTP009</org_study_id>
    <nct_id>NCT04547998</nct_id>
  </id_info>
  <brief_title>Clinical Study to Investigate the Safety and Effectiveness of RECELL for Repigmentation of Stable Vitiligo Lesions</brief_title>
  <official_title>A Prospective Blinded Within-Subject Randomized Controlled Clinical Study to Investigate the Safety and Effectiveness of RECELL for Repigmentation of Stable Vitiligo Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Avita Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Avita Medical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Prospective Blinded Within-Subject Randomized Study to evaluate the application of&#xD;
      Spray-On Skin™ Cells, prepared using the RECELL® Device for safe and effective repigmentation&#xD;
      of ablated stable vitiligo lesions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 10, 2020</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Responders for RECELL-treated areas versus Control at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>Responders are defined as study areas achieving ≥ 80% repigmentation as determined by the the Central Review Committee.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Central Review Committee categorization of repigmentation</measure>
    <time_frame>Week 24</time_frame>
    <description>Central Review Committee categorization of repigmentation (0-25%, 26-50%, 51-79% and 80-100%) at Week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central review committee assessment of color matching at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>Color matching will be rated excellent, good, moderate, or poor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject and Investigator global treatment success and donor site satisfaction</measure>
    <time_frame>Week 24</time_frame>
    <description>Subjects and Investigators to respond to satisfaction questions for their treatment areas and donor sites.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject-reported Vitiligo Noticeability Score for Week 24 vs baseline</measure>
    <time_frame>Week 24</time_frame>
    <description>Based upon photographs subject will report their vitiligo noticeability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator assessment of pigmentation responder for the study areas</measure>
    <time_frame>Week 24</time_frame>
    <description>Investigators to assess pigmentation response for study areas where response equals 80% or greater pigmentation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator assessment of repigmentation category</measure>
    <time_frame>Week 24</time_frame>
    <description>Investigator to look at subject photos and determine what percent the area has repigmented: 0-25, 26-50, 50-79 or 80-100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central Review Committee and Investigator assessment of pigmentation</measure>
    <time_frame>Week 36 and 52</time_frame>
    <description>Central Review Committee and Investigator assessment of pigmentation for the study areas at Week 36 and Week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator study area Vitiligo Area Scoring Index (VASI) scores, change from baseline</measure>
    <time_frame>Week 24</time_frame>
    <description>Evaluation of VASI score in study areas and change in score from pre-treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator assessment of color matching for the study areas</measure>
    <time_frame>Week 24</time_frame>
    <description>Color matching will be categorized as poor (0), moderate (1), good (2), or excellent (3). Hypopigmentation and hyperpigmentation, when present, will also be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central Review Committee assessment of color matching</measure>
    <time_frame>Week 36 and 52</time_frame>
    <description>Central Review Committee assessment of color matching for the study areas at Week 36 and 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Change - Vitiligo (PaGIC-V)</measure>
    <time_frame>Week 24</time_frame>
    <description>The subject's impression of their improvement is assessed using a 7-point scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Repigmentation durability</measure>
    <time_frame>Week 52</time_frame>
    <description>Repigmentation durability to be assessed by the Investigator and Central Review Committee (CRC). For RECELL responding study areas (i.e., study areas that achieved repigmentation at Week 24), the investigator and CRC will confirm by observation at the Week 52 visit, that at least 80% of the repigmentation remains relative to the subject's Week 24 photograph.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">81</enrollment>
  <condition>Vitiligo</condition>
  <arm_group>
    <arm_group_label>Spray-On Skin™ Cells 1:20 with NB-UVB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Skin cell suspension at expansion ratio 1:20 (donor area : recipient area), prepared using the RECELL System, will be applied to an ablated (de-epithelialized) area of depigmentation, followed by targeted phototherapy using NB-UVB. Each participant receive treatment of a portion of a single bisected depigmented lesion or all of a single with cell suspension prepared at 1:20.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NB-UVB only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each subject will serve as their own control, with a portion of the depigmented lesion receiving no RECELL treatment but receiving the same targeted NB-UVB as the investigational treatment area.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Spray-On Skin™ Cells 1:20 with NB-UVB</intervention_name>
    <description>Skin cell suspension at 3 expansion ratios (donor area : recipient area), prepared using the RECELL System, will be applied to an ablated (de-epithelialized) area of depigmentation, followed by targeted phototherapy using NB-UVB. Each participant will be randomized to receive treatment of a portion of their depigmented lesion with cell suspension prepared at 1:20</description>
    <arm_group_label>Spray-On Skin™ Cells 1:20 with NB-UVB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NB-UVB only</intervention_name>
    <description>Each subject will serve as their own control, with a portion of the depigmented lesion receiving no RECELL treatment but receiving the same targeted NB-UVB as the investigational treatment area.</description>
    <arm_group_label>NB-UVB only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1. Focal, segmental or generalized (i.e., nonsegmental) stable vitiligo, defined as no new&#xD;
        depigmented areas nor any depigmented areas that have expanded in size within the preceding&#xD;
        12 months, regardless of whether the areas are intended to be used as study areas.&#xD;
&#xD;
        1a. Photo documentation (current and at least 12 months prior) of the patient's depigmented&#xD;
        areas have been evaluated as stable by an independent Screening Committee.&#xD;
&#xD;
        2. The patient has not undergone topical treatment (e.g., steroids, tacrolimus) for the&#xD;
        study areas within the past 90 days.&#xD;
&#xD;
        3. The patient has not undergone phototherapy (e.g., NB-UVB) for the study areas within the&#xD;
        past 90 days.&#xD;
&#xD;
        4. The patient is a candidate for surgical intervention of a depigmented area, defined as a&#xD;
        patient who has previously been compliant with but has not satisfactorily responded to both&#xD;
&#xD;
        a. topical therapy and b. a minimum of 3 months of phototherapy.&#xD;
&#xD;
        5. The patient must have two study areas available for treatment that:&#xD;
&#xD;
          1. are of similar size (±50%),&#xD;
&#xD;
          2. are between 16cm2 and 456cm2 (contiguous),&#xD;
&#xD;
          3. are similarly sun exposed,&#xD;
&#xD;
          4. have the same extent of leukotrichia, and&#xD;
&#xD;
          5. are judged clinically as ≥90% depigmented (by area).&#xD;
&#xD;
             6. The patient is 18 years of age or older.&#xD;
&#xD;
             7. The patient is willing and able to comply with post-treatment at-home phototherapy&#xD;
             and all follow-up evaluations required by the study protocol.&#xD;
&#xD;
             8. The patient agrees to abstain from any other treatment of the study areas for the&#xD;
             duration of his/her participation in the study (52 weeks).&#xD;
&#xD;
             9. The patient agrees to abstain from enrollment in any other interventional clinical&#xD;
             trial for the duration of his/her participation in the study (52 weeks).&#xD;
&#xD;
             10. In the opinion of the investigator, the patient must be able to:&#xD;
&#xD;
        a. Understand the full nature and purpose of the study, including possible risks and&#xD;
        adverse events, b. Understand instructions, and c. Provide voluntary written informed&#xD;
        consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The study areas selected have concomitant dermatologic conditions other than vitiligo.&#xD;
&#xD;
          2. The study area selected for treatment includes the lips, eyelids, plantar surface of&#xD;
             feet, palmar surface of hands, fingertips, wrists, ankles, elbows, or knees.&#xD;
&#xD;
          3. The patient is unable to undergo the treatment area preparation.&#xD;
&#xD;
          4. Patients who are pregnant.&#xD;
&#xD;
          5. Patients with:&#xD;
&#xD;
               1. universalis vitiligo,&#xD;
&#xD;
               2. depigmented areas over &gt;30% of their body surface area,&#xD;
&#xD;
               3. depigmented lips and fingertips (lip-tip vitiligo), or&#xD;
&#xD;
               4. &gt; 3 depigmented fingertips, defined as depigmentation of the dorsal aspect of the&#xD;
                  fingertip from the distal interphalangeal joint to the tip of the digit.&#xD;
&#xD;
          6. Patients with recent history (within previous 12 months) of:&#xD;
&#xD;
               1. Koebnerization,&#xD;
&#xD;
               2. confetti-like, or&#xD;
&#xD;
               3. trichrome lesions.&#xD;
&#xD;
          7. Patients with a history of keloid formation.&#xD;
&#xD;
          8. Patients who have used a tanning salon in the past 60 days.&#xD;
&#xD;
          9. The patient has other concurrent conditions that in the opinion of the investigator&#xD;
             may compromise patient safety or study objectives.&#xD;
&#xD;
         10. Current use of medications (e.g., anticoagulants such as heparin or warfarin) that in&#xD;
             the investigator's opinion may compromise patient safety or trial objectives.&#xD;
&#xD;
         11. The patient has a known hypersensitivity to trypsin or compound sodium lactate for&#xD;
             irrigation (Hartmann's) solution.&#xD;
&#xD;
         12. Life expectancy is less than 1 year.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Elizabeth Kirshner</last_name>
    <phone>6613676869</phone>
    <email>ekirshner@avitamedical.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lisa Carothers</last_name>
    <phone>6614814663</phone>
    <email>lcarothers@avitamedical.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California, Irvine</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Ortiz</last_name>
      <email>ulloal@hs.uci.edu</email>
    </contact>
    <investigator>
      <last_name>Anand Ganesan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Keck School of Medicine, USC Dept of Dermatology</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giselle Garcia</last_name>
      <phone>323-742-3240</phone>
      <email>Giselle.Garcia@med.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Nada Elbuluk, MD, MSc, FAAD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iryna Rybak</last_name>
      <email>irybak@ucdavis.edu</email>
    </contact>
    <investigator>
      <last_name>Victor Huang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Dermatology</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexes Gonzalez</last_name>
      <phone>858-657-1004</phone>
      <email>agonzalez@clderm.com</email>
    </contact>
    <investigator>
      <last_name>Mitchel P Goldman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AboutSkin Dermatology</name>
      <address>
        <city>Greenwood Village</city>
        <state>Colorado</state>
        <zip>80111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debbie Dahler</last_name>
      <email>ddahler@aboutskinderm.com</email>
    </contact>
    <investigator>
      <last_name>Joel Cohen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Modern Dermatology</name>
      <address>
        <city>Westport</city>
        <state>Connecticut</state>
        <zip>06880</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessia Giannini</last_name>
      <phone>203-635-0770</phone>
      <email>Research Modern Dermatology &lt;research@moderndermct.com&gt;</email>
    </contact>
    <investigator>
      <last_name>Deanne Robinson, MD, FAAD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Skin Care Research, LLC</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lori Aptekar</last_name>
      <email>lori.aptekar.scr@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Eduardo Weiss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Miami Dermatology and Laser Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33173</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Moriel Daniel</last_name>
      <phone>312-503-5916</phone>
      <email>morieldaniel@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Roopal V Kundu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01581</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Celia Hartigan</last_name>
      <email>Celia.Hartigan@umassmed.edu</email>
    </contact>
    <investigator>
      <last_name>Bassel Mahmoud, MD, PhD, FAAD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Creasor, RN</last_name>
      <phone>313-916-0427</phone>
      <email>JCreaso2@hfhs.org</email>
    </contact>
    <investigator>
      <last_name>Iltefat Hamzavi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Skin Laser and Surgery Specialists</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diana Aranzazu</last_name>
      <phone>908-359-8980</phone>
      <email>Diana.Aranzazu@schweigerderm.com</email>
    </contact>
    <investigator>
      <last_name>David J Goldberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dermatology, Laser &amp; Vein Specialists of the Carolinas</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Razia Ludin, MHA,BSc, CCRC</last_name>
      <phone>704-973-3687</phone>
      <email>RaziaL@carolinaskin.com</email>
    </contact>
    <investigator>
      <last_name>Girish Munavalli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deanna DeHoff</last_name>
      <email>dehoff@musc.edu</email>
    </contact>
    <investigator>
      <last_name>Steven Kahn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas at Austin Dell Medical School</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kate Sebastian, RN,MPH</last_name>
      <email>kate.sebastian@austin.utexas.edu</email>
    </contact>
    <investigator>
      <last_name>Ammar Ahmed, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Heights Dermatology</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77008</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ginger Bliss</last_name>
      <email>gbliss@researchdrc.com</email>
    </contact>
    <investigator>
      <last_name>Alpesh Desai, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 8, 2020</study_first_submitted>
  <study_first_submitted_qc>September 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2020</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitiligo</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

